Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Petitjean, Audrey; Smith-Palmer, Jayne; Valentine, William; Tehard, Bertrand; Roze, Stephané

doi:10.1186/s12885-019-5335-8

BMC Cancer

Article metrics
Last updated: Thu, 18 Apr 2024 8:32:49 Z

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Access & Citations

3703

Article Accesses
6

Web of Science
6

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com